The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

FDA DRAFT POINTS TO CONSIDER IN THE DESIGN AND IMPLEMENTATION OF FIELD TRIALS FOR BLOOD GROUPING REAGENTS AND ANTI-HUMAN GLOBULIN

Origin/Publisher:

Freedom of Information Staff, (HFI 35), Food and Drug Administration, Rm. 12 A - 30, 5600 Fishers Lane, Rockville, MD 20857, USA, http://www.fda.gov/

Document Type:
Points to consider DRAFT
Content:
intent in performing field trials on new Blood Grouping Reagents and Anti-Human Globulin Reagents and the subsequent impact on field trial design and implementation

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK